Humacyte Inc (HUMA)
6.33
-0.09
(-1.40%)
USD |
NASDAQ |
May 17, 16:00
6.35
+0.02
(+0.32%)
After-Hours: 20:00
Humacyte Cash from Operations (TTM): -82.01M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -82.01M |
December 31, 2023 | -73.30M |
September 30, 2023 | -73.21M |
June 30, 2023 | -77.01M |
March 31, 2023 | -70.97M |
Date | Value |
---|---|
December 31, 2022 | -71.13M |
September 30, 2022 | -73.62M |
June 30, 2022 | -87.33M |
March 31, 2022 | -85.44M |
December 31, 2021 | -81.19M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-87.33M
Minimum
Jun 2022
-70.97M
Maximum
Mar 2023
-77.52M
Average
-75.31M
Median
Cash from Operations (TTM) Benchmarks
Aquestive Therapeutics Inc | -25.58M |
Adial Pharmaceuticals Inc | -6.807M |
Gritstone Bio Inc | -115.12M |
Precision BioSciences Inc | -71.63M |
Puma Biotechnology Inc | 35.61M |